title: The high prevalence of alexithymia in hemodialyzed patients with secondary hyperparathyroidism unsuppressed by medical therapy is cured by parathyroidectomy.
abstract: There are scanty data available on alexithymia in patients with end-stage renal disease, which point to an independent association with depression and social support. This study was devised to investigate the prevalence of alexithymia and sleep disorders in patients maintenance hemodialysis with insuppressible secondary hyperparathyroidism, who need parathyroidectomy (PTX), because previous data from our laboratories as well as those of others showed that this patient-group are the worst sleepers among hemodialysis patients with end-stage renal disease. A total of 40 patients needing PTX were enrolled and studied before the surgery. As for the control group, 80 patients on maintenance hemodialysis not needing PTX were enrolled. We measured alexithymia with the Toronto Alexithymia Score (TAS-20), sleep disorders with the Pittsburgh Sleep Quality Index (PSQI), and depression with Beck Depression Inventory (BDI), intact parathyroid hormone (iPTH), calcium, phosphate, use of antihypertensives, systolic and diastolic blood pressure, hemoglobin concentration, and albumin concentration. Patients needing PTX in comparison with those not needing PTX had significantly higher iPTH, calcium, and phosphate; they also had significantly higher systolic and diastolic blood pressure. They were more significantly alexithymic (P < .001), had more severe sleep disorders (P < .001), and were more depressed (P < .043). In multivariate analysis, BDI correlated significantly with iPTH concentration (r = 0.505, P < .001). A reduction of TAS-20 occurred after PTX which correlated with the number of patients on antihypertensive drugs, PSQI, BDI, hemoglobin concentration in the univariate and multivariate analysis. When TAS-20 and PSQI were adjusted for BDI (using analysis of variance) there was still a significant difference of TAS-20 and PSQI between patients needing PTX and not needing PTX (P < .001). This study confirms the high prevalence of sleep disorders in patients with unsuppressed secondary hyperparathyroidism and discloses a high prevalence of Alexithymia which is ameliorated by PTX. However, the correlation of Alexithymia with sleep disorders does not depend on depression.
authors.affiliation: Italian Institute Philosophical Studies, Naples, Italy. bluetoblue@libero.it
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: De Santo
authors.forename: Antonio
authors.initials: A
authors.lastname: Livrea
authors.forename: Natale G
authors.initials: NG
authors.lastname: De Santo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Conzo
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Bilancio
authors.forename: Salvatore
authors.initials: S
authors.lastname: Celsi
authors.forename: Massimo
authors.initials: M
authors.lastname: Cirillo
mesh_terms: D000342:Affective Symptoms / Q000150:complications* / Q000453:epidemiology / Q000628:therapy*; D002118:Calcium / Q000097:blood; D003863:Depression / Q000150:complications / Q000453:epidemiology; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000150:complications* / Q000601:surgery; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D016105:Parathyroidectomy; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis; D012893:Sleep Wake Disorders / Q000150:complications / Q000453:epidemiology
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; D002118:Calcium